Identification of A Novel Mutation in RYR1 Gene in Malignant Hyperthermia-Like Patient's Family Members

Open access

Identification of A Novel Mutation in RYR1 Gene in Malignant Hyperthermia-Like Patient's Family Members

Malignant hyperthermia (MH) is a rare pharmacogenetic disorder with an autosomal dominant inheritance that presents as a hypermetabolic response in skeletal muscle to volatile anaesthetic (halothane, isoflurane, desflurane, sevoflurane) and the depolarising muscle relaxant succinil-choline and rarely to stresses such as vigorous exercise and heat. We investigated the relatives of an individual with suspected MH and found a novel mutation in RYR1 gene. The molecular analysis of RYR1 gene revealed a novel nucleotide substitution in exon 6 - G528T (Glu-176-Asp) in four family members of the patient. The in vitro contracture test (IVCT) according to the European Malignant Hyperthermia Group (EMHG) guidelines showed a MH susceptible phenotype in two tested family members.

Allen, G. C., Rosenberg, H., Fletcher, J. E. (1990). Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility. Anesthesiology, 72(4), 619-622.

Bonciu, M., Chapelle, A., Delpech, H., Depret, T., Krivosic-Horber, R., Aime, M. R. (2007). Minor increase of endtidal CO2 during sevoflurane induced malignant hyperthermia. Pediatric Anesthesia, 17, 180-182.

Cohen, I. T., Kaplan, R. (2006). Repeat episodes of severe muscle rigidity in a child receiving sevoflurane. Paediatric Anaesthesia. 16(10), 1077-1079.

Denbrough, M. (1998). Malignant hyperthermia. Lancet, 352, 1131-1136.

Denborough, M. A., Lowell, R. H. (1960) Anaesthetic deaths in a family (letter). Lancet, 2, 45.

Greenberg, D. A. (1999). Muscle & Nerve, 22(10), 1341-1349.

Halsall, P. J., Cain, P. A., Ellis, F. R. (1979). Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognised. Brit. J. Anaesth., 51, 949-954.

Islander, G., Ranklev-Twetman, E. (1995). Evaluation of anaesthesias in malignant hyperthermia negative patients. Acta Anaesthesiol. Scand, 39(6), 819-821.

Krause, T., Gerbershagen, M. U., Fiege, M., Weisshorn, R., Wappler, F. (2004). Dantrolene—a review of its pharmacology, therapeutic use and new developments. Anaesthesia, 59(4), 364-373.

Larach, M. G., Brandom, B. W., Allen, G. C., Gronert, G. A., Lehman, E. B. (2008). Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: A report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology, 108(4), 603-611.

Ording, H., Hedengran, A. M., Skovgaard, L. T. (1991). Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol. Scand., 35(8), 711-716.

Ording, H., Brancadoro, V., Cozzolino, S., Ellis, F. R., Glauber, V., Gonano, E. F., Halsall, P. J., Hartung, E., Heffron, J. J., Heytens, L., Kozak-Ribbens, G., Kress, H., Krivosic-Horber, R., Lehmann-Horn, F., Mortier, W., Nivoche, Y., Ranklev-Twetman, E., Sigurdsson, S., Snoeck, M., Stieglitz, P., Tegazzin, V., Urwyler, A., Wappler, F. (1997). In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol. Scand., 41(8), 955-966.

Rosenberg, H., Davis, M., James, D., Pollock, N., Stwell, K. (2007). Malignant hyperthermia. Orphanet J. Rare Dis., 24, 2-21.

Scala, D., Di Martino, A., Cozzolino, S., Mancini, A., Bracco, A., Andria, B., Tammaro, A., Savoia, G. (2006). Follow-up of patients tested for malignant hyperthermia susceptibility. Eur. J. Anaesthesiol., 23(9), 801-805.

Tammaro, A., Bracco, A., Cozzolino, S., Esposito, M., Di Martino, A., Savoia, G., Zeuli, L., Piluso, G., Aurino, S., Nigro, V. (2003). Scanning for mutations of the ryanodine receptor (RYR1) gene by denaturing HPLC: Detection of three novel malignant hyperthermia alleles. Clin. Chem., 49(5), 761-768.

Urwyler, A., Deufel, T., McCarthy, T., West, S. (2001) Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. European Malignant Hyperthermia Group. Brit. J. Anaesth., 86(2), 283-287.

Wappler, F. (2001). Malignant hyperthermia. Eur. J. Anaesthesiol., 18, 632-652.

Wedel, D. J. (1992). Malignant hyperthermia and neuromuscular disease. Neuromuscular Disorders, 2(3), 157-164.

Wehner, M., Rueffert, H., Koenig, F., Neuhaus, J., Olthoff, D. (2002). Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin. Genet., 62(2), 135-146.

Journal Information

CiteScore 2017: 0.22

SCImago Journal Rank (SJR) 2017: 0.127
Source Normalized Impact per Paper (SNIP) 2017: 0.211


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 331 331 23
PDF Downloads 183 183 6